Esbriet 267 MG Oral Capsule
Idiopathic Pulmonary Fibrosis
Clinical trials
1
Developer
Excalibur Pharmaceuticals, Inc.
Overview
Esbriet 267 MG Oral Capsule is an agent tracked by PF-Atlas in the context of idiopathic pulmonary fibrosis. It appears in 1 tracked IPF clinical trial.
Esbriet 267 MG Oral Capsule clinical trials
Explore related
Medical disclaimer. This page summarizes research about Esbriet 267 MG Oral Capsule for information only. It is not medical advice. Verify approval status and evidence with the FDA and a pulmonologist.